Eledon Advances Tegoprubart In Islet Cell And Kidney Transplant Programs

Eledon Pharmaceuticals, Inc. (ELDN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Eledon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Business Highlights Successful End-of-Phase 2 meeting with FDA supports advancement of tegoprubart into a global Phase 3 kidney transplantation trial, on track to initiate in late 2026 Lo

NewcelX (Nasdaq: NCEL) said it completed a Type B Pre-IND meeting with the FDA for NCEL-101 in type 1 diabetes, with FDA feedback aligning on a regulatory path toward IND-enabling activities and a planned clinical trial. The trial would combine NCEL-101 with Eledon Pharmaceuticals’ (Nasdaq: ELDN) tegoprubart (anti-CD40L).

Eledon Pharmaceuticals (ELDN) reported updated investigator-initiated trial results for tegoprubart, an anti-CD40L antibody, in type 1 diabetes patients receiving allogeneic islet cell transplants at the University of Chicago. According to the company, all 12 patients achieved insulin independence, with mean most recent HbA1c ~5.4% and stable graft function over a median 8 months (max 22). No rejection or de novo donor-specific HLA antibodies were reported. Eledon said it will seek FDA regulator

The global battery energy storage market is projected to grow from $50.81B in 2025 to $105.96B by 2030, driven by renewable integration and grid modernization. NOMAD Power Solutions (NMAD) advanced its Vermont project to Phase 3, deploying transportable BESS units with DOE support. The $19M project includes $9.5M in DOE funding and aims to enhance grid flexibility.

Aptevo Therapeutics (APVO) stock fell 17.3% pre-market to $2.15 despite reporting 93% clinical benefit rate in a trial for a treatment-resistant leukemia. The decline is attributed to 'sell the news' reaction, potential dilution from new shares, and bearish technical trends. The broader market showed mild gains, but not enough to offset APVO's challenges.

Summit Therapeutics (SMMT) shares rose 4.8% premarket after partner Akeso reported positive overall survival data from a Phase III lung cancer trial. Ivonescimab showed a significant survival benefit over pembrolizumab in the HARMONi-2 study, though specific details were not disclosed. Akeso received marketing approval in China, but the drug remains investigational in Summit's territories. Analysts maintained a Neutral rating, citing insufficient data to change their view.